Paratek Pharmaceuticals Valuation
Based on Macroaxis valuation methodology, the company cannot be evaluated at this time. Paratek Pharmaceuticals recent Real Value cannot be determined due to lack of data. The prevailing price of Paratek Pharmaceuticals is $0.0. Our model determines the value of Paratek Pharmaceuticals from analyzing the company fundamentals such as Shares Owned By Insiders of 11.70 %, current valuation of 345.3 M, and Return On Asset of -0.18 as well as examining its technical indicators and probability of bankruptcy.
Paratek Pharmaceuticals Total Value Analysis
Paratek Pharmaceuticals is at this time anticipated to have valuation of 345.3 M with market capitalization of 127.83 M, debt of 258.41 M, and cash on hands of 57.01 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Paratek Pharmaceuticals fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
345.3 M | 127.83 M | 258.41 M | 57.01 M |
Paratek Pharmaceuticals Investor Information
About 55.0% of the company shares are owned by institutional investors. The company recorded a loss per share of 1.11. Paratek Pharmaceuticals last dividend was issued on the 31st of October 2014. The entity had 1:12 split on the 31st of October 2014. Based on the key indicators related to Paratek Pharmaceuticals' liquidity, profitability, solvency, and operating efficiency, Paratek Pharmaceuticals is not in a good financial situation at the moment. It has a very high risk of going through financial straits in April.Paratek Pharmaceuticals Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Paratek Pharmaceuticals has an asset utilization ratio of 87.39 percent. This suggests that the Company is making $0.87 for each dollar of assets. An increasing asset utilization means that Paratek Pharmaceuticals is more efficient with each dollar of assets it utilizes for everyday operations.Paratek Pharmaceuticals Ownership Allocation
Paratek Pharmaceuticals owns a total of 57.32 Million outstanding shares. Over half of Paratek Pharmaceuticals' outstanding shares are owned by third-party entities. These third-party entities are typically referred to as corporate investors that secure positions in a given instrument to benefit from reduced trade commissions. Please note that no matter how many assets the company maintains, if the real value of the company is less than the current market value, you may not be able to make money on it.Paratek Pharmaceuticals Profitability Analysis
The company reported the previous year's revenue of 150.79 M. Net Loss for the year was (63.57 M) with profit before overhead, payroll, taxes, and interest of 99.39 M.Paratek Pharmaceuticals Growth Indicators
Investing in growth stocks can be very risky. If the company such as Paratek Pharmaceuticals does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 54.4 M | |
| Forward Price Earnings | 1.7206 |
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.
Other Consideration for investing in Paratek Stock
If you are still planning to invest in Paratek Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Paratek Pharmaceuticals' history and understand the potential risks before investing.
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Global Correlations Find global opportunities by holding instruments from different markets |